Literature DB >> 18573864

Valvular heart disease: a perspective on the asymptomatic patient with severe valvular aortic stenosis.

Shahbudin H Rahimtoola1.   

Abstract

Early in 2006, the European Society of Cardiology (ESC) assigned the 2006 Denolin lecturer to provide a broad perspective on the asymptomatic patient with severe calcific valvular aortic stenosis (AS) in the older patient. Subsequently, in late 2006, American College of Cardiology/American Heart Association Guidelines and in 2007 ESC Guidelines have given the Class I recommendation to 'primary' aortic valve replacement (AVR) for asymptomatic patients with AS only to those with left ventricular dysfunction at rest and to those who only become symptomatic on exercise testing. Indications for AVR in classes IIa and IIb were provided. However, almost all of the recommendations in classes I and II were based on level of evidence C. 'Primary' AVR is that which is recommended for severe AS as opposed to AVR secondary to surgery for other cardiovascular disease.

Entities:  

Mesh:

Year:  2008        PMID: 18573864     DOI: 10.1093/eurheartj/ehn272

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Transcatheter aortic valve replacement.

Authors:  Hersh S Maniar; Alan Zojarias
Journal:  Mo Med       Date:  2012 Jul-Aug

2.  Improvement in left ventricular function assessed by tissue Doppler imaging after aortic valve replacement for severe aortic stenosis.

Authors:  Chih-Chiang Nieh; Alvin Yeng-Hok Teo; Wern Miin Soo; Glenn K Lee; Devinder Singh; Kian-Keong Poh
Journal:  Singapore Med J       Date:  2015-12       Impact factor: 1.858

3.  Computer-assisted determination of left ventricular endocardial borders reduces variability in the echocardiographic assessment of ejection fraction.

Authors:  Eva Maret; Lars Brudin; Lena Lindstrom; Eva Nylander; Jan L Ohlsson; Jan E Engvall
Journal:  Cardiovasc Ultrasound       Date:  2008-11-11       Impact factor: 2.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.